^
Association details:
Biomarker:BRAF V600E
Cancer:Ganglioglioma
Drug:Tafinlar (dabrafenib) (BRAF inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
New
Source:
Excerpt:
Adjuvant Treatment...Useful in Certain Circumstance...Pilocytic astrocytoma, PXA, ganglioglioma if BRAF V600E activating mutation…dabrafenib…
Evidence Level:
Sensitive: C1 - Off-label
  (Approved for Melanoma)
New
Excerpt:
TAFINLAR is a kinase inhibitor indicated as a single agent for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test.
Evidence Level:
Sensitive: C3 – Early Trials
New
Title:

Efficacy of Dabrafenib for three children with brainstem BRAF V600E positive ganglioglioma

Excerpt:
Retrospective description of three cases of childhood brainstem ganglioglioma with BRAFV600E mutation treated in the long-term with Dabrafenib, a specific BRAFV600E kinase inhibitor….Dabrafenib resulted in rapid tumoral regression and significant and durable clinical and radiological improvement....This targeted therapy has been well tolerated despite its long-term use of 4.8 to 5.5 years in the three patients.
DOI:
10.1007/s11060-019-03280-2
Evidence Level:
Sensitive: C3 – Early Trials
New
Source:
Title:

Recurrent ganglioglioma in adults treated with BRAF inhibitors

Excerpt:
Three patients with recurrent ganglioglioma and positive for the V600E mutation were treated with dabrafenib, a second-generation BRAF inhibitor...Best radiographic response following two cycles of dabrafenib was stable disease in two patients and partial response in one patient....Median progression-free survival was 7 months (range 4-10 months). Median overall survival from onset of dabrafenib was 12 months (range 6–16 months).
DOI:
10.2217/cns.15.40